COVID-19 crisis: Gilead announces steps to expand availability of Remdesivir in India
The pharma co is set to provide support for new manufacturing facilities, and will donate active pharmaceutical ingredients to increase production
Washington: American biopharmaceutical company Gilead has announced steps to expand the availability of Remdesivir, a key therapeutic medicine used in the treatment of COVID-19 patients, in India.
Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalised with severe disease.
"The recent surge of COVID-19 cases in India is having a devastating impact on communities and has created unprecedented pressure on health systems,” Johanna Mercier, chief commercial officer of Gilead Sciences said on Monday.
The company announced that it was providing its voluntary licensing partners technical assistance, support for addition of new local manufacturing facilities and donation of active pharmaceutical ingredient (API) to rapidly scale up the production of Remdesivir.
In addition to providing support to its licences to expand their local manufacturing capacity, Gilead will also donate at least 450,000 vials of Veklury (remdesivir) to help address the immediate needs of Indian patients, the company said.
“We are committed to doing our part to help tackle this crisis. Our immediate focus is to help address the needs of patients in India who may benefit from remdesivir as quickly as we can by working together with the government, health authorities and our voluntary licensees,” Mercier said.
All seven of Gilead’s licences based in India have significantly accelerated production of remdesivir by scaling up their batch sizes, adding new manufacturing facilities and/or onboarding local contract manufacturers across the country, it said.
While these efforts are expected to increase the availability of Remdesivir in the coming weeks, Gilead said it will also donate at least 450,000 vials of Veklury to the government of India to help ease the immediate need for treatment.
Gilead’s voluntary licensing programme for Remdesivir, established in May 2020, has already enabled access to the drug for more than 2.3 million people in more than 60 low and middle-income countries.
The programme, which builds on Gilead’s pioneering voluntary licensing model for its HIV and viral hepatitis medicines, provides long-term licences to nine manufacturers, seven of which are based in India, to enable access to remdesivir in 127 countries.
Coronavirus News Updates: Maharashtra's COVID-19 toll tops one lakh with 233 fresh deaths; state sees 12,557 new cases
Coronavirus News Updates: The recovery rate is now 95.05 percent and the fatality rate is 1.72 percent and there are 1,85,527 active cases
Coronavirus News Updates: PM speaks to Kamala Harris, appreciates US efforts for vaccine supply to India
Coronavirus News Updates: The US embassy issued a statement from Symone Sanders, senior advisor and chief spokesperson for Harris on her calls with leaders of four countries, including Modi, on the global allocation plan for the supply of the COVID-19 vaccine doses to India and other countries by the month-end
The government has said that the economic impact from the second Covid-19 wave will be less than that of the first. But economists point to signs of a growing rural economic crisis, and call for urgent relief measures to ward off long-term damage.